Stewart Parker Buys Shares of Codexis, Inc. (CDXS)

Stewart Parker purchased 66,350 shares of Codexis, Inc. on June 17, 2026.

Written by EarningsIQ · Published Jun 19, 2026, 3:01 AM EDT · Updated Jun 20, 2026, 8:00 AM EDT

Key Points

Stewart Parker bought 66,350 shares of Codexis, Inc. on June 17, 2026, showing insider confidence.
Codexis, Inc. trades at $2.57 with a market cap of $233.6 million and a 52-week high of $3.87.
Analysts maintain a 'buy' consensus with a target mean price of $6.58, reflecting positive sentiment.

On June 17, 2026, Stewart Parker acquired 66,350 shares of Codexis, Inc. (NasdaqGS: CDXS), a biotechnology company. This insider purchase suggests a vote of confidence in the company's future prospects.

Insider Buying and Selling at Codexis, Inc.

Stewart Parker wasn't the only insider buying on June 17. Christos Richards, David Smith, Rahul Singhvi, Esther Martinborough, and Stephen George Dilly each also purchased 66,350 shares of Codexis. These transactions were not part of a pre-planned trading program, indicating a direct decision to increase their stake in the company.

Other Institutional Activity in Codexis, Inc.

Institutional investors have been active in Codexis as well. Aberdeen Group PLC increased its stake by 713,870 shares to hold a total of 8,680,368 shares worth approximately $14.15 million. BlackRock, Inc. reduced its holdings by 366,967 shares, now holding 7,028,773 shares valued at around $11.46 million. Opaleye Management Inc. made a slight reduction of 4,738 shares, ending with 6,785,000 shares valued at about $11.06 million. Meanwhile, Millennium Management LLC added 862,938 shares, bringing its total to 3,998,130 shares worth roughly $6.52 million.

Codexis, Inc. Stock Snapshot

Shares of Codexis, Inc. are trading at $2.57. The company has a market cap of approximately $233.6 million. It operates with a forward P/E ratio that is not meaningful due to its current unprofitability. Codexis has a beta of 2.478, indicating higher volatility compared to the market. The stock's 52-week range is between $0.96 and $3.87, with moving averages of $2.569 (50-day) and $2.0225 (200-day). The company maintains a strong liquidity position with a current ratio of 5.364 and a quick ratio of 4.927, though it carries a debt-to-equity ratio of 168.624.

Analysts Set New Price Targets

Analysts are optimistic about Codexis, Inc., with several firms maintaining a 'buy' rating. On August 29, 2024, Cantor Fitzgerald reiterated its 'buy' rating with a price target of $11. Stifel Nicolaus also maintained a 'buy' rating with a $5 target on May 20, 2024. The consensus among analysts is a 'buy' recommendation, with a target mean price of $6.58, based on 6 analyst opinions.

About Codexis, Inc.

Codexis, Inc. is a biotechnology company based in Redwood City, California. It focuses on developing and commercializing novel enzymes using its proprietary CodeEvolver technology platform. These enzymes are used in therapeutics manufacturing, including RNAi therapeutics, through its ECO Synthesis platform. The company has partnerships with firms like Aldevron LLC and Pfizer Inc. Dr. Alison Moore, Ph.D., leads the company as CEO, and it employs around 146 people.

Bottom Line

The recent insider purchases at Codexis, Inc. highlight a strong vote of confidence from the company's leadership. While the stock is currently trading at $2.57, analysts maintain a positive outlook with a 'buy' consensus and a target mean price of $6.58. Investors should note that insider transactions and institutional moves are key factors to watch, though the data reflects past activity rather than current positions.